Skip to content
Screener

Mirum Pharmaceuticals, Inc. MIRM EV / EBITDA

EV / EBITDA at other companies

Gilead Sciences logo
Gilead SciencesGILD
17.5×-0.7×
ALN
Alnylam PharmaceuticalsALNY
36.7×—
Arrowhead Research logo
Arrowhead ResearchARWR
27.4×—
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
7.9×—
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
7.7×-10.6×
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
4.3×-1.7×

Other financials

Income statement

See full
Revenue$176.2M+37.9%
Operating income-$42.5M-753%
Net income-$67.2M-1,047%
EPS (diluted)-$1.06-783%

Balance sheet

See full
Cash & equivalents$262.7M+39.4%
Total debt$12.9M+29.2%
Total equity-$10.4M-104%
Total assets$1.0B+44.0%

Cash flow

See full
Operating cash flow-$44.3M-468%
CapEx$23.0K-81.7%
Free cash flow-$44.3M-472%

Valuation

See full
Market cap$6.45B+144%
Enterprise value$6.2B+151%
P/S10.4×+4.3×

Profitability

See full
Operating margin-134.9%-151pp
Net margin-139.2%-156pp
FCF margin-37%—

Returns & leverage

See full
Return on equity-335.8%-377pp
Debt / equity0.1×0.0×
Current ratio2.9×-0.3×

Where this comes from

Calculated from Mirum Pharmaceuticals, Inc.’s reported figures.

enterprise value/ebitda=1,820.6×

Based on the most recent quarter.

The source filing: Mirum Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026. Open the filing →

Filed
Aug 5, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001759425-26-000045

FAQ

What is Mirum Pharmaceuticals, Inc.'s EV / EBITDA?
Mirum Pharmaceuticals, Inc. (MIRM) reported EV / EBITDA of 1,820.6× in Q4 2025.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.

Ask your AI about Mirum Pharmaceuticals, Inc.'s ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude